Article

Toward Personalized Cell Therapies: Autologous Menstrual Blood Cells for Stroke

Department of Neurosurgery and Brain Repair, University of South Florida College of Medicine, 12901 Bruce B. Downs Boulevard, Tampa, FL 33612, USA.
BioMed Research International (Impact Factor: 2.71). 11/2011; 2011:194720. DOI: 10.1155/2011/194720
Source: PubMed

ABSTRACT Cell therapy has been established as an important field of research with considerable progress in the last years. At the same time, the progressive aging of the population has highlighted the importance of discovering therapeutic alternatives for diseases of high incidence and disability, such as stroke. Menstrual blood is a recently discovered source of stem cells with potential relevance for the treatment of stroke. Migration to the infarct site, modulation of the inflammatory reaction, secretion of neurotrophic factors, and possible differentiation warrant these cells as therapeutic tools. We here propose the use of autologous menstrual blood cells in the restorative treatment of the subacute phase of stroke. We highlight the availability, proliferative capacity, pluripotency, and angiogenic features of these cells and explore their mechanistic pathways of repair. Practical aspects of clinical application of menstrual blood cells for stroke will be discussed, from cell harvesting and cryopreservation to administration to the patient.

Full-text

Available from: Hiroto Ishikawa, Apr 01, 2015
0 Bookmarks
 · 
126 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human endometrium contains mesenchymal stem cells (eMSC) which have the ability to differentiate into three cell lineages and the potential in therapeutic applications. We hypothesize that using environmental induction in culture media such as dexamethasone, human recombinant insulin and human epidermal growth factor (hEGF) can differentiate endometrial stem cells into myoblast. These agents have a broad range of effects in myoblast differentiation in-vitro. We used immunohystochemistry analysis and RT –PCR to evaluate the presence of skeletal muscle - specific proteins some of which are expressed in the early stage of differentiation including myoD and Desmin which expressed at later stages of differentiation. In conclusion eMSC can differentiate in culture media which contains above mentioned factors and use for therapeutic purpose in muscular degenerative disease.
    Iranian journal of pharmaceutical research (IJPR) 05/2014; 13(2):659-664. · 0.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The tremendous regenerative capacity of the human endometrium is based on the activity of adult stem cells. Endometrial stem cells are mainly located in the basal layer, but could also be successfully isolated from the functional layer, which is shed during menstruation. Menstrual blood-derived stem cells (MenSCs) can be obtained by noninvasive procedures. They are characterized by high proliferative potential, long-term culturing properties, mesenchymal stem cell-like marker expression and multilineage differentiation potential. MenSCs have been successfully employed as therapeutics in animal models of myocardial infarction, stroke, Duchenne muscular dystrophy, and critical limb ischemia. Their allogeneic application is not associated with immunological side effects and does not promote tumor formation in vivo. Pilot studies have confirmed their safety upon applications in humans, and phase 1/2 clinical studies on their safety and therapeutic efficacy are ongoing. A systematic banking of immunoprofiled MenSCs will expand the therapeutic repertoire beyond autologous stem cell transplantations.
    Regenerative Medicine Using Non-Fetal Sources of Stem Cells, XXVII, 2015 edited by Niranjan Bhattacharya, Phillip G. Stubblefield, 09/2014: chapter Chapter 7: Characteristics and Therapeutic Potential of Menstrual Blood-Derived Stem Cells: pages 55-70; Springer., ISBN: 978-1-4471-6541-5
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Traumatic brain injury (TBI) is a serious public health problem accounting for 1.4 million emergency room visits by US citizens each year. Although TBI has been traditionally considered an acute injury, chronic symptoms reminiscent of neurodegenerative disorders have now been recognized. These progressive neurodegenerative-like symptoms manifest as impaired motor and cognitive skills, as well as stress, anxiety, and mood affective behavioral alterations. TBI, characterized by external bumps or blows to the head exceeding the brain's protective capacity, causes physical damage to the central nervous system with accompanying neurological dysfunctions. The primary impact results in direct neural cell loss predominantly exhibiting necrotic death, which is then followed by a wave of secondary injury cascades including excitotoxicity, oxidative stress, mitochondrial dysfunction, blood-brain barrier disruption, and inflammation. All these processes exacerbate the damage, worsen the clinical outcomes, and persist as an evolving pathological hallmark of what we now describe as chronic TBI. Neuroinflammation in the acute stage of TBI mobilizes immune cells, astrocytes, cytokines, and chemokines toward the site of injury to mount an antiinflammatory response against brain damage; however, in the chronic stage, excess activation of these inflammatory elements contributes to an "inflamed" brain microenvironment that principally contributes to secondary cell death in TBI. Modulating these inflammatory cells by changing their phenotype from proinflammatory to antiinflammatory would likely promote therapeutic effects on TBI. Because neuroinflammation occurs at acute and chronic stages after the primary insult in TBI, a treatment targeting neuroinflammation may have a wider therapeutic window for TBI. To this end, a better understanding of TBI etiology and clinical manifestations, especially the pathological presentation of chronic TBI with neuroinflammation as a major component, will advance our knowledge on inflammation-based disease mechanisms and treatments.
    Neuropsychiatric Disease and Treatment 01/2015; 11:97-106. DOI:10.2147/NDT.S65815 · 2.00 Impact Factor